Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
September 2, 2002
- Sankyo Starts e-Promotion
September 2, 2002
- Takara Bio: High-Sensitivity DNA Chip Template "Takara-Hubble Slide"
September 2, 2002
- Schering-Plough Launches Ono's Leukotriene Antagonist Pranlukast in Mexico
September 2, 2002
- Wakamoto: TESTMATE Pylori Antigen EIA before NHI Price Listing
September 2, 2002
- Toyama, Taisho to Respect Each Other's Independence
September 2, 2002
- Hitachi High-Tech to Market bioMerieux's Blood Coagulation Products
September 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 2, 2002
- Fujirebio: Half-year Sales Down 4.8% to \12,209 Mil.
September 2, 2002
- General Hospitals' Earnings Up 3 Years in a Row: SWMSC Report
September 2, 2002
- Medical Fee Revision Favors Major Dispensing Pharmacies: Nomura Report
September 2, 2002
- 70% of Patients Don't Like Substitutive Generics: Survey
September 2, 2002
- MEDICAL DEVICE NEWS IN BRIEF
September 2, 2002
- Ivermectin, Micafungin Recommended for Approval by CDFS
September 2, 2002
- NEW PRODUCTS
September 2, 2002
- NHI Price Listing Not Pending for Any More Products
September 2, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
September 2, 2002
- Role of "General Manufacturing and Marketing Manager" Needs to Be Clarified
September 2, 2002
- BULLETIN
September 2, 2002
- Report Calls For Dosage, Administration in Child Patients
September 2, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…